Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)

May 24, 2018 updated by: Susan J. Hayflick

Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)

The purpose of this study is to learn whether blood flow in the brain is normal in people with pantothenate kinase-associated neurodegeneration (PKAN). Specifically, preliminary data suggest a region of the brain called the globus pallidus (GP), a key region affected by PKAN, may have reduced blood flow. Standard MRI and perfusion scanning techniques will be used to learn about cerebral blood flow in the globus pallidus and compare it to blood flow in other brain regions as well as to healthy controls.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health & Science University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years to 73 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The PKAN group consists of individuals in the United States diagnosed with PKAN.

Description

Inclusion Criteria:

  • diagnosis of PKAN confirmed by MRI and gene testing
  • able to undergo MRI for approximately 1 hour without sedation

Exclusion Criteria:

  • deep brain stimulators or other conditions that warrant avoidance of a strong magnetic field
  • previous reaction to gadolinium (Gd) contrast agent
  • acute or chronic kidney dysfunction
  • pregnant and/or nursing at time of study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
PKAN
This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
Healthy volunteers
This is a control group of healthy volunteers, matched with the PKAN group for age and sex.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ASL-derived cerebral blood flow(CBF)
Time Frame: Single MRI
The unit of analyses will be the subject and the primary comparison will be the globus pallidus CBF between PKAN and healthy controls.
Single MRI

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Susan J. Hayflick

Collaborators

Oregon Health and Science University
Oregon Clinical and Translational Research Institute

Investigators

  • Principal Investigator: Susan J Hayflick, MD, Oregon Health and Science University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2013

Primary Completion (Actual)

October 1, 2017

Study Completion (Actual)

January 1, 2018

Study Registration Dates

First Submitted

April 18, 2013

First Submitted That Met QC Criteria

April 22, 2013

First Posted (Estimate)

April 23, 2013

Study Record Updates

Last Update Posted (Actual)

May 29, 2018

Last Update Submitted That Met QC Criteria

May 24, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 8777

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pantothenate Kinase-associated Neurodegeneration (PKAN)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe